Navigation Links
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
Date:2/3/2009

ition of monoamine oxidase-B [MAO-B] and dopamine uptake) and reduction of glutamatergic activity by inhibiting glutamate release.

About Parkinson's disease

Parkinson's disease is a degenerative disorder of the central nervous system that often impairs the patient's motor skills and speech. Parkinson's disease belongs to a group of conditions called movement disorders. It is characterized by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement (akinesia). The primary symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Secondary symptoms may include high-level cognitive dysfunction and subtle language problems. Parkinson's disease is both chronic and progressive. It is estimated that more than 3 million people in the industrialized countries suffer from Parkinson's disease.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility (Gonal-f(R), follitropin alfa), endocrine and cardiometabolic disorders (Glucophage(R), metformin); (Concor(R), bisoprolol); (Euthyrox(R), levothyroxine); (Saizen(R) and Serostim(R), somatropin). Not all products are available in all markets.

With an annual R&D expenditure of around EUR 1bn,
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
2. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
3. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
4. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
5. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
11. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Vermillion, Inc. (NASDAQ: VRML), a multivariate ... hold a conference call on Thursday, August 14, 2014, at ... quarter ended June 30, 2014. Financial results will be issued ... Vermillion,s Chairman, President and CEO James LaFrance will ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. ...
(Date:7/31/2014)... YORK , July 31, 2014 TB ... better, faster and affordable treatments for tuberculosis (TB), announced ... Vice President, Market Access. Ms. Robertson joins the organization ... company,s business in Sub-Saharan Africa and Eastern ... oversee the TB Alliance,s efforts to ensure beneficial new ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... the eighth annual Prix Galien USA ... biomedical industry,s highest accolade and recognizes the technical, scientific ... and devices. This year brings the highest ... Galien USA . Nominees include biomedical ...
Breaking Medicine Technology:Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... ... C Clarification of Oncogenic Pathways ... Potential Benefit in Liver Transplantation, MILAN, April 26 , - Systems Biology ... Meeting of the European,Association for the Study of the Liver (EASL), experts reported advances ...
... YORK, April 24 PulmoBioTech Inc. (OTC,Bulletin Board: PLMO) ... the areas that it will be investigating as part ... are:, 1. Efficacy Binding Studies 2. ... 4. Pyrogenicity 5. Immunological Testing 6. ...
Cached Medicine Technology:Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4PulmoBioTech Announces Details of Its Regulatory Approval Experiments 2PulmoBioTech Announces Details of Its Regulatory Approval Experiments 3
(Date:7/31/2014)... have asthma, you may have an asthma action plan with ... to changes and understand when symptoms are getting worse and ... doing well, yellow means your asthma has worsened and action ... guidelines are now available to help your allergist steer you ... from the red zone. , "Management of acute loss of ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars , ... East Horn Road in Lake Leelanau. Joining the Northern Loop ... is the 25th winery along the trail. The winery will ... events, making its trail event debut during the Harvest Stompede ... David and Faye Mathia opened the boutique winery in the ...
(Date:7/31/2014)... 2014 0-6 Pack Abs has finally been ... therapist expert Dr. James Vegher. Together they have launched ... relieve digestive issues, tone core muscles, improve posture, eliminate achy ... core exercises used to re-train the body in order to ... 0-6 Pack Abs review, Shane Michaels, a fitness ...
(Date:7/31/2014)... July 31, 2014 Adventist Health ... the U.S. including Florida Hospital Tampa, Florida Hospital ... Florida Hospital North Pinellas, Florida Hospital Wesley Chapel, ... Sebring, Florida Hospital Heartland Medical Center Lake Placid ... Networks list of Most Wired Hospitals and Health ...
(Date:7/31/2014)... Cosmetic Town has introduced a secure ... Doctors will be able to verify their patients before ... which guarantees their authenticity. This will help prospective ... receive information that has been verified to come from ... Cosmetic Town to filter out fake patients who leave ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 3Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2
... Venture," a one-day workshop about the basics of technology ... takes to launch a startup venture. Presentations ... intellectual property issues and business plans. Participants include Erica ... at Carnegie Mellon whose research focuses on the role ...
... 16, 2010Announcing the launch of the Liebert Mobile ... latest news, resources, press releases, research, and multimedia ... information across the biomedical, biotechnology, medicine, surgery, and ... is available with this free application. ...
... The ... ... its new Prodigy Count-a-dose™ April 1, a precise and safe syringe-filling device for the blind ... can easily measure and mix two insulins at one time. The device had been pulled ...
... A ... released today. This new concept protects consumers by enabling them to pay less, get more, and ... and legal problems relating to the construction. , ... (PRWEB) March 16, 2010 -- Stop Ripping Me Off! is the title of ...
... puts cost per life-year gained at about $66,200 ... agents for metastatic colon cancer improve patient survival but ... Emory University in Atlanta analyzed data from 4,665 patients, ... between 1995 and 2005. Compared to those who received ...
... bothered by treatment,s effects, study finds , TUESDAY, March ... enough radiation to shield patients from prostate cancer,s return ... as tricky as once thought, new research shows. , ... time. In fact, 10 years after treatment, prostate cancer ...
Cached Medicine News:Health News:Prodigy Re-Launches Syringe-Filling System for Blind and Low-Vision Diabetics 2Health News:Stop Ripping Me Off! Is the Title of a New Consumer Protection Book Being Released Today 2Health News:Stop Ripping Me Off! Is the Title of a New Consumer Protection Book Being Released Today 3Health News:Are New Chemo Treatments Cost-Effective? 2Health News:Prostate Cancer Radiation Side Effects May Subside With Time 2
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... agreement between Brook Brothers and Luxottica ... by lightweight materials and a slender ... the unique features of the style ... with classic style and affordable to ...
... Ray-Ban brand debuted in 1937 with the ... was added to Luxottica Group's brand portfolio ... show business celebrities since day one, Ray-Bans ... far the best-selling sunglasses in the world. ...
... Group has been manufacturing the Anne Klein ... Klein eyewear collections are designed for an ... wear Anne Klein eyewear identifies herself with ... refined career woman who is image-conscious and ...
Medicine Products: